



2023 CRO


BENCHMARKING DATA




(2023) Rare disease / orphan drugs will comprise much more of my company's development activities over the next two years (n=299)




(2022) Rare disease / orphan drugs will comprise much more of my company's development activities over the next two years (n=260)



(2021) Rare disease / orphan drugs will comprise much more of my company's development activities over the next two years (n=272)




(2020) Rare disease / orphan drugs will comprise much more of my company's development activities over the next two years (n=329)



(2019) Rare disease / orphan drugs will comprise much more of my company's development activities over the next two years (n=508)




(2023) Management of CROs and other service providers is taking up too much of my time (n=299)




(2022) Management of CROs and other service providers is taking up too much of my time (n=260)







(2023) My organization will increase the use of specialized site identification companies over the next two years (n=299)



(2023) My organization will spread its outsourced work over more CROs over the next two years (n=299)





(2023) My organization will run a clinical trial within the next two years where the majority of activities occur in the participant's home (n=299)




(2022) My organization will run a clinical trial within the next two years where the majority of activities occur in the participant's home (n=260)




(2021) My organization will run a clinical trial within the next two years where the majority of activities occur in the participant's home (n=272)




(2020) My organization will run a clinical trial within the next two years where the majority of activities occur in the participant's home (n=329)




(2023) Decentralized clinical trials will be a major component of my organization's clinical portfolio within two years (n=299)



(2022) Virtual/ decentralized clinical trials will be a major component of my organization's clinical portfolio within two years (n=260)



(2021) Virtual/ decentralized clinical trials will be a major component of my organization's clinical portfolio within two years (n=272)



(2020) Virtual/ decentralized clinical trials will be a major component of my organization's clinical portfolio within two years (n=329)



STRONGLY AGREE

MODERATELY AGREE

SLIGHTLY AGREE

SLIGHTLY DISAGREE

MODERATELY DISAGREE

STRONGLY DISAGREE


(2023) Clinical trial designs at my company are focusing on enrolling a demographically diverse population (n=299)



(2022) Clinical trial designs at my company are focusing on enrolling a demographically diverse population (n=260)



(2021) Clinical trial designs at my company are focusing on enrolling a demographically diverse population (n=272)



(2020) Clinical trial designs at my company are focusing on enrolling a demographically diverse population (n=329)

